Literature DB >> 18332997

A salvage treatment for solid liver metastasis after radical resection of Klatskin tumour.

Yuji Nakagawa1, Takeshi Todoroki, Tadashi Kondo, Toru Kawamoto, Nobuhiro Ohkohchi, Kiyoshi Ohara.   

Abstract

BACKGROUND: Long-term survival has not been described following surgical resection for liver metastasis after radical resection of an advanced hilar bile duct carcinoma (Klatskin tumour). One such patient who developed liver metastasis after radical treatment for stage IVA (pTNM) hilar cholangiocarcinoma has survived 5.5 years after resection of the liver metastasis followed by chemotherapy. CASE REPORT: A 50-year-old man developed a solid liver metastasis in segment VIII 17 months after radical resection of a stage IVA (pT3 pN I MO) Klatskin tumour followed by postoperative radiotherapy (54 Gy) and systemic chemotherapy (oral UFT 450 mg/day plus intravenous cisplatin 20 mg on 5 consecutive days each month). The patient is alive at 7 years after the primary resection followed by resection of the liver metastasis plus further systemic chemotherapy comprising oral UFT combined with intravenous adriamycin (ADM) and mitomycin C (MMC).
CONCLUSION: Aggressive salvage resection surgery can be an effective component of a multidisciplinary treatment regimen, even for a postoperative liver metastasis that developed after radical resection of an advanced Klatskin tumour, provided that the metastasis is solid and has not failed local-regional control.

Entities:  

Year:  2003        PMID: 18332997      PMCID: PMC2020601          DOI: 10.1080/13651820310001333

Source DB:  PubMed          Journal:  HPB (Oxford)        ISSN: 1365-182X            Impact factor:   3.647


  5 in total

Review 1.  Radiotherapy as a component of multidisciplinary treatment of bile duct cancer: a surgeon's perspective.

Authors:  T Todoroki
Journal:  J Hepatobiliary Pancreat Surg       Date:  2001

2.  Benefits of adjuvant radiotherapy after radical resection of locally advanced main hepatic duct carcinoma.

Authors:  T Todoroki; K Ohara; T Kawamoto; N Koike; S Yoshida; H Kashiwagi; M Otsuka; K Fukao
Journal:  Int J Radiat Oncol Biol Phys       Date:  2000-02-01       Impact factor: 7.038

3.  Treatment strategy for patients with middle and lower third bile duct cancer.

Authors:  T Todoroki; T Kawamoto; N Koike; K Fukao; J Shoda; H Takahashi
Journal:  Br J Surg       Date:  2001-03       Impact factor: 6.939

4.  Radical resection of hilar bile duct carcinoma and predictors of survival.

Authors:  T Todoroki; T Kawamoto; N Koike; H Takahashi; S Yoshida; H Kashiwagi; Y Takada; M Otsuka; K Fukao
Journal:  Br J Surg       Date:  2000-03       Impact factor: 6.939

Review 5.  Chemotherapy for bile duct carcinoma in the light of adjuvant chemotherapy to surgery.

Authors:  T Todoroki
Journal:  Hepatogastroenterology       Date:  2000 May-Jun
  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.